首页> 外文期刊>Nature reviews neuroscience >Inhibition of USP4 attenuates pathological scarring by downregulation of the TGF-beta/Smad signaling pathway
【24h】

Inhibition of USP4 attenuates pathological scarring by downregulation of the TGF-beta/Smad signaling pathway

机译:USP4的抑制通过TGF-Beta / Smad信号通路的下调衰减病理瘢痕形成

获取原文
获取原文并翻译 | 示例
           

摘要

Pathological scarring is a result of the hypertrophy of scar tissue during tissue repair following trauma. The aim of the present study was to assess the effect of ubiquitin-specific protease 4 (USP4) silencing on pathological scarring, and to evaluate the mechanistic basis for the effect. An MTT assay was used to assess cell viability. Immunoprecipitation (IP) was used to determine ubiquitination levels of the TGF-beta receptor (T beta R)I and Smad7. Tumor formation was assessed by injecting keloid fibroblasts. Hematoxylin and eosin staining was used to detect pathological changes in tumor tissue. Reverse transcription quantitative polymerase chain reaction and western blot analysis assays were used to evaluate the expression levels of T beta RI and Smad7. Compared with the untreated control animals, cell viability and the expression of T beta RI and Smad7 increased significantly in animals treated with TGF-beta. Short hairpin RNA for USP4 (shUSP4) decreased the cell viability of negative control cells, TGF-beta-induced cellular proliferation, and the expression of T beta RI and Smad7. IP experiments indicated that the ubiquitination level of T beta RI was decreased following USP4 silencing. There was no remarkable difference in the structure of scar tissue among the various animal groups at 14 days following treatment, while the necrotic area of the scar tissue in the shUSP4 and vialinin A (USP inhibitor)-treated animals increased significantly at the 28th and 42nd day compared with the control animals. At days 14, 28 and 42, the expression levels of T beta RI and Smad7 in the shUSP4 and vialinin A-treated animals were significantly decreased compared with the control animals (P<0.05). In summary, interference with or inhibition of USP4 prevented the activity of the TGF-beta/Smad pathway signaling and inhibited the formation of pathological scars.
机译:病理瘢痕形成是瘢痕组织在组织修复期间的肥大症的结果。本研究的目的是评估泛素特异性蛋白酶4(USP4)沉默于病理瘢痕的作用,并评估机械基础的效果。 MTT测定用于评估细胞活力。免疫沉淀(IP)用于确定TGF-β受体(TβR)I和Smad7的泛素化水平。通过注射瘢痕疙瘩成纤维细胞来评估肿瘤形成。苏木精和曙红染色用于检测肿瘤组织的病理变化。逆转录定量聚合酶链反应和Western印迹分析测定用于评估TβRi和Smad7的表达水平。与未处理的对照动物相比,在用TGF-β处理的动物中,细胞活力和TβRI和Smad7的表达显着增加。 USP4(SHUSP4)的短发夹RNA降低了阴性对照细胞,TGF-Beta诱导的细胞增殖和TβRi和Smad7的表达的细胞活力。 IP实验表明,USP4沉默后,TβRi的泛素化水平降低。治疗后14天,各种动物组中的瘢痕组织结构没有显着差异,而SHUSP4和Vialinin A(USP抑制剂) - 治疗动物的瘢痕组织的坏死区域在第28和42次上显着增加与对照动物相比的日子。在第14,28和42天,与对照动物相比,SHUSP4和Vialinin A处理的动物中的TβRI和Smad7的表达水平显着降低(P <0.05)。总之,对USP4的干扰或抑制阻止了TGF-β/ Smad途径信号传导的活性并抑制了病理瘢痕的形成。

著录项

  • 来源
    《Nature reviews neuroscience》 |2019年第2期|共7页
  • 作者单位

    Nanchang Univ Affiliated Hosp 1 Dept Oral &

    Maxillofacial Surg 17 Yongwai Zheng St Nanchang;

    Nanchang Univ Affiliated Hosp 1 Dept Oral &

    Maxillofacial Surg 17 Yongwai Zheng St Nanchang;

    Nanchang Univ Affiliated Hosp 1 Dept Oral &

    Maxillofacial Surg 17 Yongwai Zheng St Nanchang;

    Nanchang Univ Affiliated Hosp 1 Dept Oral &

    Maxillofacial Surg 17 Yongwai Zheng St Nanchang;

    Nanchang Univ Affiliated Hosp 1 Dept Oral &

    Maxillofacial Surg 17 Yongwai Zheng St Nanchang;

    Nanchang Univ Affiliated Hosp 1 Dept Oral &

    Maxillofacial Surg 17 Yongwai Zheng St Nanchang;

    Nanchang Univ Affiliated Hosp 1 Dept Oral &

    Maxillofacial Surg 17 Yongwai Zheng St Nanchang;

    Nanchang Univ Affiliated Hosp 1 Dept Oral &

    Maxillofacial Surg 17 Yongwai Zheng St Nanchang;

    Nanchang Univ Affiliated Hosp 1 Dept Oral &

    Maxillofacial Surg 17 Yongwai Zheng St Nanchang;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 神经生理学;
  • 关键词

    pathological scarring; ubiquitin-specific protease 4; transforming growth factor-beta/Smad signaling pathway;

    机译:病理瘢痕;特异性素特异性蛋白酶4;转化生长因子-β/ Smad信号通路;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号